Medtronic received Food and Drug Administration approval for the BrainSense Adaptive deep brain stimulation (DBS) device for people with Parkinson’s disease, a movement disorder of the nervous ...

Medtronic (NYSE:MDT) has won FDA approval for a deep brain stimulation system for Parkinson’s disease. The approval is for BrainSense Adaptive deep brain stimulation (DBS)and BrainSense ...

Now Medtronic has enhanced its Percept™ DBS neurostimulators with exclusive BrainSense™ Adaptive technology, introducing aDBS for people living with Parkinson's. This feature personalizes ...

Now Medtronic has enhanced its Percept™ DBS neurostimulators with exclusive BrainSense™ Adaptive technology†, introducing aDBS for people living with Parkinson's. This feature personalizes ...

Medtronic announced on Monday that the Food and Drug Administration approved its BrainSense Adaptive deep brain stimulation technology and BrainSense Electrode Identifier to treat Parkinson’s ...

Medtronic's BrainSense aDBS personalizes Parkinson's therapy in real-time, minimizing manual adjustments for better symptom control. BrainSense Electrode Identifier speeds up initial DBS ...

Medtronic previously set the stage for the technology with an FDA approval in 2021 for deep-brain stimulation hardware that could sense and record changes in local electric field potentials.

Deep brain stimulation (DBS) has been instrumental in managing Parkinson's symptoms for over three decades. Medtronic's Percept™ DBS neurostimulators now incorporate BrainSense™ Adaptive ...

On Monday, the FDA approved Medtronic plc’s (NYSE:MDT) BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier (EI) for patients with Parkinson’s disease. Deep brain ...